Form 8-K Citius Pharmaceuticals, For: Mar 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Citius Pharmaceuticals (CTXR) Granted Nasdaq Hearing
March 13, 2024 4:34 PM EDTOn March 12, 2024, Citius Pharmaceuticals (NASDAQ: CTXR) received formal notice that the Nasdaq Stock Market LLC (Nasdaq) granted our request for an extension through September 9, 2024 (the Extension Notice) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Bid... More



